Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

Sorafenib is the first drug of proved clinical efficacy on hepatocellular carcinoma (HCC) as it
provides a modest but significant increase in survival rate in patients with advanced HCC [1] …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC)
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …

Tumor cells express vascular endothelial growth factor (VEGF) that can activate VEGF
receptors (VEGFRs) on or within tumor cells to promote growth in an angiogenesis …

Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide.
Currently, sorafenib is the standard first-line drug for patients with advanced HCC. However …

Introduction Sorafenib is the only drug approved by the Food and Drug Administration for
metastatic hepatocellular carcinoma (HCC). Triptolide, a diterpene triepoxide, exhibits …

Purpose: To evaluate the combination of erlotinib and bevacizumab in subjects with
hepatocellular carcinoma (HCC) who are not candidates for local therapy. Patients and …

Sorafenib is a multi-kinase inhibitor applicable to hepatocellular carcinoma (HCC), but its
limited therapeutic effects are a major problem to be solved. Here, we show that blockade of …